Coumarin derivatives: An updated patent review (2012-2014)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 12, 2014, Pages 1323-1347

  Katsori, Anna Maria ^a   Hadjipavlou Litina, Dimitra ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anti Alzheimer; Anticancer; Antimicrobial; Antioxidant; Antiviral; Coumarin; Cytotoxicity

Indexed keywords

3 ARYL 8 ALLYL 7 HYDROXY(METHOXY)COUMARIN DERIVATIVE; 3 TRIFLUOROMETHYL COUMARIN DERIVATIVE; 4 (1,2,3 TRIAZOL 1 YL)COUMARIN DERIVATIVE; 4 ARYLCOUMARIN DERIVATIVE; 4 ARYLQUINOLINE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARBOXYLIC ACID DERIVATIVE; CHALCONE DERIVATIVE; CHLOROPROPOXY DERIVATIVE OF 7 OXO COUMARIN; CHROMONE DERIVATIVE; COUMARIN DERIVATIVE; COUMARIN MACROMOLECULE POLYMER; COUMARIN SKELETON POLYCYCLIC COMPOUND; DIAGNOSTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYCYCLIC HYDROCARBON; POLYMER; PYRROLE COUMARIN DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THEANINE COUMARIN CARBOXYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANTI ACNE ACTIVITY; ANTIMITOTIC ACITIVTY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; BRAIN DISEASE; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; EXCISION REPAIR; FERULA; FERULA FERULAEOIDES; HEPATITIS C; HERPES SIMPLEX VIRUS; HUMAN; HYBRIDIZATION; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER PROTECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; STRUCTURE ANALYSIS; ULTRAVIOLET RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COUMARINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; PATENTS AS TOPIC; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84911864372     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.972368     Document Type: Review

References (89)

1. Borges F, Roleira F, Milhazes N, et al. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 2005;12(8):887-916
2. Kontogiorgis C, Detsi A, Hadjipavlou-Litina D. Coumarin-based drugs: a patent review (2008 - present). Expert Opin Ther Pat 2012;22(4):437-54
3. Xu P, Peng Y, Wang C, et al. inventors Peking University, Peop. Rep. China. assignee. Coumarin derivatives as mitogen-activated and extracellular signal-regulated kinase inhibitor, and their preparation. CN102964326A; 2013
4. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK cascade for the treatment of cancer. Oncogene 2007;26(22):3291-310
5. De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(S2):S17-27
6. Wang C, Zhang H, Xu F, et al. Substituted 3-Benzylcoumarins as Allosteric MEK1 Inhibitors: design, Synthesis and Biological Evaluation as Antiviral Agents. Molecules 2013;18(5):6057-91
7. Yuan J, Song F, Xie X, et al. inventors; Northwest Normal University, Peop. Rep. China. assignee. Coumarins polymer with anti-tumor activity and its preparation method. CN103012671A; 2013
8. Liu Q, Duan H, Luan J, et al. Effects of theanine on growth of human lung cancer and leukemia cells as well as migration and invasion of human lung cancer cells. Cytotechnology 2009;59(3):211-17
9. Zhang G, Zhang Y. inventors; Yantai University, Peop. Rep. China. assignee. Application of DTClC and DTBrC in preparing drug for preventing and treating cancer. CN103110621A; 2013
10. Ma L, Zhang B, Chen Y, et al. inventors; Beijing Hanmi Pharmaceutical Co., Ltd., Peop. Rep. China. assignee. Coumarin compound useful in treatment of cancer and its preparation. CN103172606A; 2013
11. Li R, Wei Y. inventors; Sichuan University, Peop. Rep. China. assignee. Five-membered urea ring-fused coumarin derivatives as PI3K/mTOR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103254203A; 2013
12. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Res 2008;68(19):8022-30
13. Wei C, Gao N. inventors; Shanxi University, Peop. Rep. China. assignee. Preparation of coumarin derivative as antitumor agent. CN103275071A; 2013
14. Matsunaga T, Nishinaga M, Saito T, Osada H; Kanazawa University, Japan. assignee. Nucleotide excision repair inhibitor, antitumor agent, and UV therapy enhancer. JP2013221018A; 2013
15. Chen Y, He F, Ma C, et al. inventors; Third Military Medical University, PLA, Peop. Rep. China. assignee. Coumarin skeleton polycyclic compound useful in treatment of cancer and its preparation. CN103408530A; 2013
16. Zou J, Cao X, Li D, Pan X. inventors; Soochow University, Peop. Rep. China. assignee. Method for preparing 3-trifluoromethyl coumarin derivative. CN103554074A; 2014
17. Cao X-H, Pan X, Zhou P-J, et al. Manganese(iii)-mediated direct Csp2-H radical trifluoromethylation of coumarins with sodium trifluoromethanesulfinate. Chem Commun 2014;50(25):3359-62
18. Zhang X, Yang Y, Zhao M, et al. A class of Trp-Trp-AA-OBzl: synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis. Eur J Med Chem 2011;46(8):3410-19
19. Zhang J, Wang X, Li H, Xu G. inventors; Capital Medical University, Peop. Rep. China. assignee. Preparation of peptide containing coumarin derivatives for treatment of cancer. CN102898502A; 2013
20. Ma L, Zhang B, Li M, et al. inventors; Beijing Hanmi Pharmaceutical Co., Ltd., Peop. Rep. China. assignee. Preparation of coumarin derivatives useful in treating tumor and/or inflammation. WO2012171488A1; 2012
21. Li R, Zhao Y, Song X, Wei Y. inventors; Sichuan University, Peop. Rep. China. assignee. 4-(1,2,3-triazol-1-yl)coumarin derivatives and its preparation method and application. CN102746281A; 2012
22. Zhang W, Li Z, Zhou M, et al. Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. Bioorg Med Chem Lett 2014;24(3):799-807
23. Combes S, Daras E, Peyrot V, et al. inventors; Universite de Marseille, Fr. assignee. Derivatives of 4-arylcoumarin and 4-arylquinoline as inhibitors of drug transporters and their preparation and use as antineoplastic agents. WO2012136910A1; 2012
24. Wind NS, Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011;2011:967419
25. Song Z, Jin Y, Li D, Jiang D. inventors; Jilin University, Peop. Rep. China. assignee. 3-Aryl-8-allyl-7-hydroxy (methoxy)coumarins as antitumor drugs and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN102675273A; 2012
26. Liu Z-H, Li D-J, Jiang D, et al. Design, synthesis and antitumor activity in vitro of a series of 3-arylcoumarins. Chem Res Chin Univ 2013;29(6):1125-8
27. Fortin S, Bérubé G. Advances in the development of hybrid anticancer drugs. Expert Opin Drug Discov 2013;8(8):1029-47
28. Sashidhara KV, Kumar A, Kumar M, et al. inventors; Council of Scientific & Industrial Research, India., assignee. Coumarin-chalcones as anticancer agents. US20130210909A1; 2013
29. Sashidhara KV, Kumar A, Kumar M, et al. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg Med Chem Lett 2010;20(24):7205-11
30. Zhiwei C, Weike S, Jianhao B, Xiaojing Y. inventors; Zhejiang University of Science and Technology, China., assignee. Quinoline coumarin derivate and preparation method and application thereof. CN102584841A; 2012
31. Ren F, Chen S, Li L, et al. inventors; NCPC New Drug Research and Development Co., Ltd., Peop. Rep. China. assignee. Coumarin-like compounds, preparation method and application thereof. CN102532084A; 2012
32. Supuran C, Dedhar S, Carta F, et al. inventors; Metasignal Therapeutics Inc., Can.; Universite Montpellier 2 Sciences et Techniques; CNRS - Dire. assignee. Carbonic anhydrase inhibitors with antimetastatic activity. WO2012070024A1; 2012
33. Wei Y, Ma C, Hattori M, et al. inventors; Guiyang College of Traditional Chinese Medicine, Peop. Rep. China. assignee. Coumarins application and its extraction method from daphne papyracea. CN103027909A; 2013
34. Yuan Y, Xu J. inventors; Sun Yat-Sen University, Peop. Rep. China. assignee. Benzo alpha-pyrone compound as gamma-type human herpesvirus resisting medicine. CN103070858A; 2013
35. Zhang P, Yang Y, Wang Z, et al. inventors; Zhejiang Academy of Medical Sciences, Peop. Rep. China. assignee. Preparation of stilbene derivative as selective estrogen receptor modulator. CN103058832A; 2013
36. Li G, Huang J, Meng H, et al. inventors; Peop. Rep. China. assignee. Sesquiterpene coumarin and sesquiterpene chromone compounds extracted from Ferula ferulaeoides. CN103113382A; 2013
37. He H, He L, Wang T, et al. inventors; Xi'an Jiaotong University, Peop. Rep. China. assignee. Pyrrole-coumarin Compounds Useful in Treatment of Hypertension and Their Preparation. CN103408554A; 2013
38. Denisenko PP, Tarasenko AA, inventors; Russia. assignee. Chloropropoxy derivatives of 7-oxo-coumarin, having tranquilizing and hepatoprotective action. RU2452732C2; 2012
39. Chen Y, Yu Y, Wang W, et al. inventors; Changchun University of Science and Technology, Peop. Rep. China. assignee. Fraxinus mandshurica extract for treating rheumatoid arthritis. CN103110700A; 2013
40. Naiki M, Okada T, Sawada K, Ogino T. inventors; Nippon Zoki Pharmaceutical Co., Ltd., Japan. assignee. Coumarin derivatives and pharmaceutical compositions containing them for treatment of arthropathy. WO2014046224A1; 2014
41. Wu L, Zhang J, Zeng J. inventors; Gannan Medical University, Peop. Rep. China. assignee. Process for synthesis of murrayone and its application in preventing and treating osteoarthritis. CN102603694A; 2012
42. Chen J, Xie X, Han S, Zhang F. inventors; Zhejiang University, Peop. Rep. China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences. assignee. Preparation of 3-substituted coumarin derivatives useful for preventing/treating the diseases caused by CB2 receptor. CN103265517A; 2013
43. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 2006;30(S1):S13-18
44. Liu H, Ye X, Duan Y, et al. inventors; Zhengzhou University, Peop. Rep. China. assignee. Preparation of 1,2,3-triazolyl dithiocarbamate compounds containing coumarin mother nucleus as histone demethylase LSD1 inhibitors. CN103319466A; 2013
45. Ye X-W, Zheng Y-C, Duan Y-C, et al. Synthesis and biological evaluation of coumarin-1,2,3-triazole-dithiocarbamate hybrids as potent LSD1 inhibitors. Med Chem Commun 2014;5(5):650-4
46. Somesh S, Ashish S, Kavita S, Sandip K. inventors; Piramal Enterprises Ltd., India. assignee. A method of treatment for acne and an anti-acne formulation comprising a coumarin compound. WO2013164841A2; 2013
47. Goettig P, Magdolen V, Brandstetter H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010;92(11):1546-67
48. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007;1776(1):22-31
49. Reboud-Ravaux M, Yerroum-El Amri C, Tan X, et al. inventors; Universite Pierre et Marie CURIE Paris 6, Fr. assignee. Use of coumarin derivatives for the preparation of drugs for treating skin diseases. US20140148480A1; 2014
50. Liu T, Mu Q, Jibens S, Xie H. inventors; Fudan University, Peop. Rep. China. assignee. Coumarin-series natural product, and its preparation method and application. CN103387582A; 2013
51. Damu GLV, Wen Q, Cui S, et al. inventors; Southwest University, Peop. Rep. China. assignee. Method for preparation of coumarin triazole and its application. CN102796085A; 2012
52. Davies PO. Multi-drug-resistant tuberculosis. In: Madkour MM, editor. Tuberculosis. Springer; Berlin, Heidelberg: 2004. p. 809-37
53. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375(9728):1830-43
54. Schinkovitz A, Gibbons S, Stavri M, et al. Ostruthin: an antimycobacterial coumarin from the roots of Peucedanum ostruthium. Planta Med 2003;69(4):369-71
55. Parmar VS, Prasad AK, Raj HG, et al. inventors; University of Delhi, India; Vallabhbhai Patel Chest Institute. assignee. Coumarin compounds for the treatment of mycobacterial infections. WO2012137224A1; 2012
56. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991;26(3-4):335-75
57. Anderle C, Stieger M, Burrell M, et al. Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 2008;52(6):1982-90
58. Flatman RH, Eustaquio A, Li SM, et al. Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob Agents Chemother 2006;50(4):1136-42
59. Heide L, Alt S. inventors; Eberhard-Karls-Universitaet Tuebingen, Germany. assignee. New antibiotics consisting of a gyrase inhibitor with a catechin structural unit for improved up-take by siderophore transporters into the cell, and a process for their production and use as drugs. DE102010055566A1; 2012
60. Alt S, Burkard N, Kulik A, et al. An Artificial Pathway to 3,4-Dihydroxybenzoic Acid Allows Generation of New Aminocoumarin Antibiotic Recognized by Catechol Transporters of E. coli. Chem Biol 2011;18(3):304-13
61. Möllmann U, Heinisch L, Bauernfeind A, et al. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 2009;22(4):615-24
62. Liu G, Chen N, Sun M, et al. inventors; Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. Preparation of coumarin derivative and application for preventing and treating serious brain disease. CN103450134A; 2013
63. Liu G, Chen N, Sun M, et al. inventors; Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. Application of coumarin derivative in preventing/treating major brain diseases. CN103446154A; 2013
64. Li G, Wang D, Sun M, et al. Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice. J Med Chem 2010;53(4):1741-54
65. Song XY, Hu JF, Sun MN, et al. IMM-H004, a novel coumarin derivative compound, protects against amyloid beta-induced neurotoxicity through a mitochondrial-dependent pathway. Neuroscience 2013;242:28-38
66. Song X-Y, Hu J-F, Sun M-N, et al. IMM-H004, a novel coumarin derivative compound, attenuates the production of inflammatory mediatory mediators in lipopolysaccharide-activated BV2 microglia. Brain Res Bull 2014;106:30-8
67. Pan Y, Yang S, Han L, Teng B. inventors; Peking University, Peop. Rep. China. assignee. Preparation and application of 4-methyl-7-hydroxy-8-(1-hydroxyethyl)coumarin. CN102584763A; 2012
68. Sun H. inventor; Beijing Hexin Feifan Biotechnology Co., Ltd., Peop. Rep. China. assignee. Substrate, reagent and method for determining activity of N-acetyl-α-glucosaminidase. CN103484525A; 2014
69. Chao J, Zhang Y, Zhang Y. inventors; Shanxi University, Peop. Rep. China. assignee. Coumarin derivative, preparation method and application. CN103570701A; 2014
70. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44(2):129-46
71. Hyogo H, Yamagishi S-I. Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease. Curr Pharm Des 2008;14(10):969-72
72. Ramasamy R, Vannucci SJ, Yan SSD, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005;15(7):16R-28R
73. Vistoli G, De Maddis D, Cipak A, et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013;47(S1):3-27
74. Zheng Z, Zhu Q, Shi X, et al. inventors; Guangzhou Consun Pharmaceutical Research Co., Ltd., Peop. Rep. China. assignee. Application of coumarin derivative in preparation of AGEs formation inhibitor. CN102846598A; 2013
75. Li F, Hu J, Wang J, Han B. inventors; China Tobacco Guangdong Industrial Co., Ltd., Peop. Rep. China. assignee. A coumarin derivative as antioxidant and its preparation. CN103601711A; 2014
76. Li F, Hu J, Wang J. inventors; China Tobacco Guangdong Industrial Co., Ltd., Peop. Rep. China. assignee. Coumarin derivative as antioxidant and its preparation. CN103601710A; 2014
77. Yang S, Pan Y, Han L, et al. inventors; Huaihai Institute of Technology, Peop. Rep. China. assignee. Method for preparation of coumarin derivative and its application. CN102775374A; 2012
78. Lee YS, Ryu JH, Nam SO, Park DH. inventors; Kyunghee University, Industry Academic Cooperation Foundation, S. Korea. assignee. Coumarin derivative as acetylcholinesterase inhibitor and method for the preparation thereof. KR2012040596A; 2012
79. Rollinger JM, Hornick A, Langer T, et al. Acetylcholinesterase Inhibitory Activity of Scopolin and Scopoletin Discovered by Virtual Screening of Natural Products. J Med Chem 2004;47(25):6248-54
80. Nam SO, Park DH, Lee YH, et al. Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem 2014;22(4):1262-7
81. Kulkarni MV, Kulkarni GM, Lin CH, Sun CM. Recent advances in coumarins and 1-azacoumarins as versatile biodynamic agents. Curr Med Chem 2006;13(23):2795-818
82. Sahoo SS, Shukla S, Nandy S, Sahoo HB. Synthesis of novel coumarin derivatives and its biological evaluations. Eur J Exp Biol 2012;2(4):899-908
83. Reddy KR, Mamatha R, Babu MS, et al. Synthesis and Antimicrobial Activities of Some Triazole, Thiadiazole, and Oxadiazole Substituted Coumarins. J Heterocycl Chem 2014;51(1):132-7
84. Smyth T, Ramachandran VN, Smyth WF. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. Int J Antimicrob Agents 2009;33(5):421-6
85. Jain P, Joshi H. Coumarin: chemical and Pharmacological Profile. J App Pharm Sci 2012;2(6):236-40
86. Burke AS, FitzGerald GA. Analgesic-antipyretic and antiinflammatory agents; pharmacotherapy of Gout. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11 edition. McGraw-Hill Education, New York; 2005. p. 1211-18
87. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaides DN. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr Pharm Des 2004;10(30):3813-33
88. Floc'h F. Coumarin in plants and fruits: implication in perfumery. Perf Flav 2002;27:32-6
89. Lacy A, O'Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004;10(30):3797-811